Pheon Therapeutics Raises $68M in Series A Financing

Pheon Therapeutics, a London, UK-based Antibody Drug Conjugate company, has raised $68 million in Series A funding. The round was led by Brandon Capital, Forbion, and Atlas Venture, with participation from Research Corporation Technologies. Pheon Therapeutics is advancing a pipeline of monotherapies for novel targets and/or with novel payloads based on Antibody Drug Conjugates (ADCs). The company intends to use the funds to advance its lead ADC program to clinical proof-of-concept and establish a pipeline of novel ADCs.

Pheon Therapeutics Secures $68 Million Series A for ADC Development

Pheon Therapeutics is a London, UK-based Antibody Drug Conjugate company developing a pipeline of monotherapies for targets and/or with payloads. The company is advancing a pipeline of monotherapies for novel targets and/or with novel payloads based on Antibody Drug Conjugates (ADCs). ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.

Pheon Therapeutics is a London, UK-based Antibody Drug Conjugate company developing a pipeline of monotherapies for targets and/or with payloads. The company is advancing a pipeline of monotherapies for novel targets and/or with novel payloads based on Antibody Drug Conjugates (ADCs) that offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments.

3 years ago

Pheon Therapeutics Secures $68 Million Series A for ADC Development

ProblemLife Sciences

Solution

Covered on